| Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Carry cholesterol & TG to tissues: Forms a platform for clot formation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Carries dietary fat to tissues |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Removes cholesterol from tissues to liver |  | 
        |  | 
        
        | Term 
 
        | Atorvastatin (Lipitor) Simvastatin (Zocor)
 Rosuvastatin (Crestor)
 |  | Definition 
 
        | HMG-CoA reductase inhibitor Inhibits cholesterol synthesis in liver --> decrease LDL-C in serum. Upregulates LDL receptors  --> increase catabolic clearance of serum LDL-C
 Significant decrease serum LDL-C
 Modest increase HDL-C, decrease TG
 May also decrease C-reactive protein
 Lipitor produces most rapid decrease in LDL-C
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Associated w/ inflammatory process in atherosclerosis |  | 
        |  | 
        
        | Term 
 
        | Liver Function Test (LFT): Atorvastatin (Lipitor)
 Rosuvastatin (Crestor)
 |  | Definition 
 
        | Monitor at 12 wks, then every 6 months |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Monitor at 6 & 12 months & 3 months if 80mg/day is used
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | All decrease risk of MI &/or mortality (but not for 2 yrs) All well absorbed PO
 Administer in evening (not needed in Lipitor): increase hepatic cholesterol synthesis at night
 SE: hepatotoxicity, do not take while pregnant
 |  | 
        |  | 
        
        | Term 
 
        | Gemfibrozil (Lopid) Fenofibrate (Tricor)
 Ezetimibe (Zetia)
 |  | Definition 
 
        | Fibric acid derivatives Increase lipoprotein lipase activity; decrease lipolysis in adipose issue; decrease hepatic uptake of fatty acids
 Effectively decrease TG & VLDL-C; increase HDL-C
 Concurrent use w/ statins may increase risk of myositis & rhabdomyolysis. Also increases risk of hepatotoxicity *Monitor LFTs
 |  | 
        |  | 
        
        | Term 
 
        | Cholestyramine (Questran) Colesevelam (Welchol)
 Ezetimibe (Zetia)
 |  | Definition 
 
        | Bile Acid sequesterants Bind to bile acids in intestines --> fecal excretion. Body upregulates LDL receptors --> increase catabolism of LDL-C in liver. Blocks cholesterol absorption
 *May interfere w/ fat & fat-soluble vit. absorption; interferes w/ absorption of other drugs: bid/tid dosing (take 1h before or 4h after)
 |  | 
        |  | 
        
        | Term 
 
        | Nicotinic acid (Niacin, Niaspan) Is a vitamin
 |  | Definition 
 
        | Inhibits lipolysis in adipose tissue; decreases hepatic production of VLDL-->decrease serum TG & LDL-C Least $$ of all; *most effective at decreasing TG & increasing HDL-C
 *Monitor LFTs as w/ statins
 Use caution in diabetics & gout
 SE: cutabneous flushing; decreases w/ continued use
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Less than or equal to 200 mg/dL Treat w/ diet
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 200-399 mg/dL Treat w/ diet & possibly then drugs
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Greater than or equal to 400 mg/dL Treat w/ diet & drugs
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Fish oil (Lovaza as prescription pill) Some evidence for flax seed oil
 Complaints: fish odor & taste, & GI disturbances
 Take w/ meals
 |  | 
        |  |